Literature DB >> 17611735

Ablation of the gene encoding p66Shc protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation.

S Menini1, C Iacobini1, C Ricci1, G Oddi1, C Pesce2, F Pugliese1, K Block3, H E Abboud3, M Giorgio4, E Migliaccio4, P G Pelicci4, G Pugliese5.   

Abstract

AIMS/HYPOTHESIS: AGEs have been implicated in renal disease associated with ageing, diabetes and other age-related disorders. Reactive oxygen species (ROS) promote formation of AGEs, which cause AGE-receptor-mediated ROS generation with activation of signalling pathways leading to tissue injury and further AGE accumulation. ROS generation is regulated by the Src homology 2 domain-containing transforming protein C1 (Shc1) isoform p66(Shc), whose deletion has been shown to protect from tissue injury induced by ageing, diabetes, hyperlipidaemia and ischaemia-reperfusion by preventing oxidative stress. This study was aimed at assessing the role of p66(Shc) in the modulation of oxidative stress and oxidant-dependent renal injury induced by AGEs.
METHODS: For 10 weeks, male p66 (shc) knockout (KO) and wild-type (WT) mice were injected with 60 microg/day albumin modified or unmodified by N epsilon-(carboxymethyl) lysine (CML). Mice were then killed for the assessment of renal function and structure, as well as systemic and renal tissue oxidative stress.
RESULTS: Upon CML injection, KO mice, in contrast to WT mice, showed no or only mild forms of proteinuria, glomerular hypertrophy, mesangial expansion, glomerular sclerosis, renal/glomerular cell apoptosis and extracellular matrix upregulation. Moreover, KO mice had lower circulating and tissue AGEs than WT mice and unchanged plasma isoprostane 8-epi-prostaglandin-F(2alpha) levels, renal/glomerular CML, 4-hydroxy-2-nonenal, AGE receptor and NAD(P)H oxidase 4 (NOX4) content (and expression of the corresponding genes), and nuclear factor kappaB activation (NFkappaB). Mesangial cells from KO mice exposed to CML showed no or slight increase in ROS levels and NFkappaB activation, again at variance with WT cells. CONCLUSIONS/
INTERPRETATION: These data indicate that p66(Shc) participates in the pathogenesis of AGE-dependent glomerulopathy by mediating AGE-induced tissue injury and further AGE formation through ROS-dependent mechanisms involving NFkappaB activation and upregulation of Nox4 expression and NOX4 production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611735     DOI: 10.1007/s00125-007-0728-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  50 in total

Review 1.  Advanced glycation end product receptor-mediated cellular dysfunction.

Authors:  Angelika Bierhaus; Per M Humpert; David M Stern; Bernd Arnold; Peter P Nawroth
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

Review 2.  Diabetes and advanced glycoxidation end products.

Authors:  Amy G Huebschmann; Judith G Regensteiner; Helen Vlassara; Jane E B Reusch
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

3.  Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway.

Authors:  E Migliaccio; S Mele; A E Salcini; G Pelicci; K M Lai; G Superti-Furga; T Pawson; P P Di Fiore; L Lanfrancone; P G Pelicci
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

4.  Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression.

Authors:  Ling Li; Geneviève Renier
Journal:  Metabolism       Date:  2006-11       Impact factor: 8.694

5.  Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice.

Authors:  P A Craven; M F Melhem; S L Phillips; F R DeRubertis
Journal:  Diabetes       Date:  2001-09       Impact factor: 9.461

6.  Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress.

Authors:  Elisa Pagnin; Gianpaolo Fadini; Renzo de Toni; Antonio Tiengo; Lorenzo Calò; Angelo Avogaro
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

7.  Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.

Authors:  H Vlassara; H Fuh; T Donnelly; M Cybulsky
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

8.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.

Authors:  H Vlassara; H Fuh; Z Makita; S Krungkrai; A Cerami; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.

Authors:  Y M Li; M Steffes; T Donnelly; C Liu; H Fuh; J Basgen; R Bucala; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Sos-mediated activation of rac1 by p66shc.

Authors:  Firdous A Khanday; Lakshmi Santhanam; Kenji Kasuno; Tohru Yamamori; Asma Naqvi; Jeremy Dericco; Artem Bugayenko; Ilwola Mattagajasingh; Andrea Disanza; Giorgio Scita; Kaikobad Irani
Journal:  J Cell Biol       Date:  2006-03-06       Impact factor: 10.539

View more
  30 in total

1.  Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.

Authors:  Gang Xi; Xinchun Shen; Yashwanth Radhakrishnan; Laura Maile; David Clemmons
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

2.  Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease.

Authors:  R Derungs; G G Camici; R D Spescha; T Welt; C Tackenberg; C Späni; F Wirth; A Grimm; A Eckert; R M Nitsch; L Kulic
Journal:  Mol Psychiatry       Date:  2016-07-19       Impact factor: 15.992

Review 3.  Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.

Authors:  Dmitry B Zorov; Magdalena Juhaszova; Steven J Sollott
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

4.  Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.

Authors:  Fabian Bock; Khurrum Shahzad; Hongjie Wang; Stoyan Stoyanov; Juliane Wolter; Wei Dong; Pier Giuseppe Pelicci; Muhammed Kashif; Satish Ranjan; Simone Schmidt; Robert Ritzel; Vedat Schwenger; Klaus G Reymann; Charles T Esmon; Thati Madhusudhan; Peter P Nawroth; Berend Isermann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

5.  Chronic nicotine exposure augments renal oxidative stress and injury through transcriptional activation of p66shc.

Authors:  Istvan Arany; Jeb Clark; Dustin K Reed; Luis A Juncos
Journal:  Nephrol Dial Transplant       Date:  2013-01-16       Impact factor: 5.992

6.  Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes.

Authors:  A Riad; D Westermann; S Van Linthout; Z Mohr; S Uyulmaz; P M Becher; H Rütten; P Wohlfart; H Peters; H-P Schultheiss; C Tschöpe
Journal:  Diabetologia       Date:  2008-09-30       Impact factor: 10.122

Review 7.  New aspects of p66Shc in ischaemia reperfusion injury and other cardiovascular diseases.

Authors:  Fabio Di Lisa; Marco Giorgio; Peter Ferdinandy; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2016-04-14       Impact factor: 8.739

Review 8.  Cardiovascular determinants of life span.

Authors:  Yi Shi; Giovanni G Camici; Thomas F Lüscher
Journal:  Pflugers Arch       Date:  2009-09-12       Impact factor: 3.657

9.  Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice.

Authors:  Alexey A Tomilov; Vincent Bicocca; Robert A Schoenfeld; Marco Giorgio; Enrica Migliaccio; Jon J Ramsey; Kevork Hagopian; Pier Giuseppe Pelicci; Gino A Cortopassi
Journal:  J Biol Chem       Date:  2009-11-05       Impact factor: 5.157

10.  FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice.

Authors:  Carla Iacobini; Stefano Menini; Claudia Blasetti Fantauzzi; Carlo M Pesce; Andrea Giaccari; Enrica Salomone; Annunziata Lapolla; Marica Orioli; Giancarlo Aldini; Giuseppe Pugliese
Journal:  Br J Pharmacol       Date:  2017-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.